v3.25.4
Identifiable Intangible Assets, Net and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) - USD ($)
$ in Millions
Dec. 31, 2025
Dec. 31, 2024
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount $ 104,006 $ 103,397
Finite-lived intangible assets, accumulated amortization (72,496) (67,549)
Finite-lived intangible assets, net 31,510 35,848
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets 22,221 19,563
Intangible assets, gross carrying amount 126,227 122,961
Identifiable Intangible Assets, Net 53,731 55,411
IPR&D [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets [1] 21,760 18,893
Licensing Agreements and Other [Member]    
Indefinite-lived Intangible Assets [Line Items]    
Total indefinite-lived intangible assets [2] 460 670
Developed Technology Rights [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount [3] 100,630 99,397
Finite-lived intangible assets, accumulated amortization [3] (70,172) (65,044)
Finite-lived intangible assets, net [3] 30,458 34,353
Brands [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount [4] 1,035 1,277
Finite-lived intangible assets, accumulated amortization [4] (1,035) (992)
Finite-lived intangible assets, net [4] 0 285
Licensing Agreements and Other [Member]    
Finite-Lived Intangible Assets [Line Items]    
Finite-lived intangible assets, gross carrying amount 2,341 2,724
Finite-lived intangible assets, accumulated amortization (1,289) (1,513)
Finite-lived intangible assets, net $ 1,052 $ 1,210
[1] The increase in the gross carrying amount primarily reflects $8.0 billion for the acquisition of Metsera (see Note 2A), partially offset by impairments of $3.9 billion (see Note 4) and the transfers to developed technology rights noted above.
[2] The decrease in the gross carrying amount reflects an impairment of $210 million (see Note 4).
[3] The increase in the gross carrying amount primarily reflect the transfer of $600 million and $590 million from IPR&D to developed technology rights for Padcev and talazoparib (Talzenna), respectively, as well as the impact of foreign exchange, partially offset by impairments of $560 million (see Note 4).
[4] The decrease in the gross carrying amount reflects an impairment of $240 million (see Note 4).